AstraZeneca: Lupus Erythematosus, Systemic trials

The registry lists 46 Lupus Erythematosus, Systemic studies with AstraZeneca as lead sponsor. 19 are open to participants now and 11 have results posted.

Phase 1 7Phase 2 11Phase 3 9Phase 4 1No phase 20(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus ErythematosusRecruitingNCT07751848Phase 3
• Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued TreatmentRecruitingNCT07691970Phase 3
• Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)Not yet recruitingNCT07688980Phase 1
• A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus ErythematosusRecruitingNCT07630714Phase 2
• Saphnelo Use in Females of Child-bearing PotentialNot yet recruitingNCT07431775
• A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus ErythematosusRecruitingNCT07430306Phase 3
• NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine CareRecruitingNCT07424261
• Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.RecruitingNCT07330245
• Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE ParticipantsRecruitingNCT07201558Phase 1
• Observational Study Investigating Demographic and Clinical Characteristics of SLE Patients in EgyptNot yet recruitingNCT07144514
• Anifrolumab Pregnancy StudyRecruitingNCT07049653
• Anifrolumab Malignancy and Serious Infections StudyRecruitingNCT07000110
• A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.RecruitingNCT06916806Phase 1
• A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLERecruitingNCT06897930Phase 1/2
• The Anifrolumab PRIM ProgramRecruitingNCT06795893
• Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab UsersRecruitingNCT06659029
• Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab UsersRecruitingNCT06594068Phase 4
• INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World UseRecruitingNCT06314282
• An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsRecruitingNCT05835310Phase 3
• Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)CompletedNCT04931563Phase 3Results posted
• A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin ManifestationsCompletedNCT02962960Phase 2Results posted
• Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus ErythematosusCompletedNCT02446912Phase 3Results posted
• Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus ErythematosusCompletedNCT02446899Phase 3Results posted
• An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in AdultsCompletedNCT01753193Phase 2Results posted
• Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.CompletedNCT01559090Phase 2Results posted
• A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus ErythematosusCompletedNCT01438489Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus ErythematosusCompletedNCT01283139Phase 2Results posted
• A Safety and Tolerability Study of MEDI-570 in Systemic Lupus ErythematosusTerminatedNCT01127321Phase 1Results posted
• A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.CompletedNCT01031836Phase 2Results posted
• A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or MyositisCompletedNCT00979654Phase 2Results posted
• Clinical and Demographic Features of Patients With Moderate to Severe Active Systemic Lupus Erythematosus in RussiaCompletedNCT06759519
• This Project Aims to Understand the Needs of Rheumatologists and Other Specialties in the Care of Patients With SLECompletedNCT06698900
• Anifrolumab Real-world Treatment Outcomes in Systemic Lupus ErythematosusActive, not recruitingNCT06673043
• AZAHAR Study To Describe Anifrolumab in a Real-World SettingCompletedNCT06626945
• A Study of GC012F Injection in Subjects With Refractory Systemic Lupus ErythematosusActive, not recruitingNCT06530849Phase 1/2
• Long-Term Organ Damage: Anifrolumab Versus Real-World Standard of Care in Adult Patients With Active Systemic Lupus ErythematosusCompletedNCT06485674
• The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)CompletedNCT06056778
• Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs.CompletedNCT06046534
• A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice.Active, not recruitingNCT05637112
• SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)Active, not recruitingNCT05141201
• Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus NephritisActive, not recruitingNCT05138133Phase 3
• Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE)CompletedNCT05001698Phase 1
• Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus ErythematosusActive, not recruitingNCT04877691Phase 3
• Anifrolumab Early Access ProgramNo longer availableNCT04750057
• Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)CompletedNCT03189875
• A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With LupusCompletedNCT00657189Phase 2